Abivax S.a.

This study tested a daily pill called ABX464 (obefazimod) as a long-term maintenance therapy for people with moderate to severe ulcerative colitis. 217 patients who completed a prior 16-week induction study took the drug for up to 96 weeks. The main goal was to see how many patie…

This study tested an experimental drug called ABX464 in 355 adults with moderate to severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could reduce symptoms like diarrhea, bleeding, and colon inflammation. Participants receiv…

This study looked at the long-term safety and effectiveness of a daily pill called ABX464 in 40 adults with moderate to severe rheumatoid arthritis. Participants had already completed 12 weeks of treatment in an earlier study. The goal was to see if ABX464 can help keep the disea…

This study tested a once-daily pill called ABX464 (obefazimod) in 639 people with moderate-to-severe ulcerative colitis who had not responded well to other treatments. The goal was to see if the drug could help bring about remission and improve bowel inflammation within 8 weeks. …

This study tested a new daily pill, ABX464, for people with moderate to severe ulcerative colitis who did not get better with other treatments. About 636 adults and teens took either 25 mg, 50 mg, or a placebo for 8 weeks. The main goal was to see if the drug could help achieve r…